ブレイン・コンピュータ・インターフェース2026：Neuralinkの実績・Synchronの安全記録・次に来るもの

In January 2024 a 29-year-old quadriplegic named Noland Arbaugh became the first human to receive a Neuralink brain implant. Within weeks he was playing chess and video games with his thoughts. By early 2026 he had logged thousands of hours of continuous neural interface use, and Neuralink had expanded its trial to over a dozen participants. Arbaugh’s implant records from the motor cortex; the company decodes the signals and maps them to cursor movement, so that what he intends to do with a hand becomes what happens on the screen.

A brain-computer interface turns neural activity into a digital command; newer systems also send signals the other way. Medical devices are the furthest along; consumer headsets are already on shelves; the privacy and consent rules for both are still being drafted.

Three paths into the brain

Invasive BCIs give the highest fidelity. Neuralink’s N1 chip, implanted directly into the motor cortex, uses 1,024 electrode threads, each thinner than a human hair, to record neural signals. BrainGate, the academic consortium behind much of the foundational research, has shown paralyzed patients controlling robotic arms, typing on screens and operating wheelchairs by thought.

Minimally invasive BCIs take a middle route. Synchron’s Stentrode, a stent-like device inserted through the jugular vein and lodged in a blood vessel near the motor cortex, needs no open brain surgery. It reads neural signals through the vessel wall, at lower resolution than a cortical implant and with far lower surgical risk. Synchron holds FDA breakthrough device designation and has run human trials since 2022; patients have controlled digital interfaces and sent messages by thought.

Non-invasive BCIs trade signal quality for reach. EEG headsets from companies such as Emotiv and Muse pick up broad patterns of neural activity through the skull, and functional near-infrared spectroscopy (fNIRS) measures changes in blood oxygenation in the brain. These devices cannot read individual thoughts. They do reliably register attention, relaxation and cognitive load, and they are already sold to consumers in meditation apps, focus-training tools and game controllers that respond to mental state.

Each generation of hardware records more channels at lower cost than the last.

Medicine first

Paralysis and locked-in syndrome. An estimated 5.4 million people live with paralysis in the United States alone. BrainGate’s clinical trials have let ALS patients write emails, browse the internet and keep up social contact that the disease would otherwise cut off. These patients can think and reason as before; what they have lost is the ability to move or speak, and the implant gives them a channel out.

Treatment-resistant depression. Deep brain stimulation (DBS), a related neurotechnology that delivers electrical impulses to targeted brain regions, has worked in patients for whom medication and therapy failed. Closed-loop systems, which watch for neural biomarkers of depressive states and stimulate only when needed, are in clinical trials at the University of California, San Francisco. The approach treats depression as a circuit problem to be regulated in real time rather than a chemical imbalance to be corrected with drugs.

Epilepsy. NeuroPace’s RNS System, already FDA-approved, monitors brain activity continuously and delivers targeted stimulation to head off seizures. Over 4,000 patients have been implanted. Clinical data show a median seizure reduction of 75% over time.

Neurodegenerative disease. Early research suggests BCIs and neurostimulation may slow cognitive decline in Alzheimer’s and Parkinson’s patients. The evidence is preliminary. Real-time neural monitoring combined with AI analysis opens lines of work that did not exist five years ago.

Beyond the clinic

Gaming and entertainment. Valve’s Gabe Newell has talked publicly about brain-computer interfaces as the future of gaming: systems that adjust difficulty, story and sensory load to the player’s emotional state in real time.

Productivity and focus. Enterprise uses are appearing in air traffic control, surgical theaters and military operations, where monitoring cognitive load and fatigue in real time can prevent serious errors. A system that detects flagging attention can reassign tasks or change break schedules.

Meditation and wellness. Consumer EEG headsets from companies such as Muse give real-time neurofeedback during meditation, turning brainwave patterns into audio cues. The global meditation app market passed $4 billion in 2025, and hardware-assisted mindfulness is its fastest-growing segment.

Whatever a meditation headset records is stored by the company that sold it.

Japan

RIKEN’s Center for Brain Science has been mapping neural circuits and developing brain-machine interface technologies for over two decades. The University of Tokyo’s NeuroIntelligence initiative studies how the brain encodes information, work that feeds directly into next-generation BCI design. Osaka University has demonstrated a BCI that lets patients control a robotic hand from decoded neural signals with fine dexterity.

29% of Japan’s population is over 65, and the share is rising. Stroke and neurodegenerative disease rise with it, and the national health system is already stretched by the world’s oldest population. The demand for a BCI that gives a stroke patient back the use of a hand, or lets an Alzheimer’s patient keep communicating, is not hypothetical in Japan.

The FDA has granted breakthrough device designations to several BCI companies, shortening the path to market. The EU AI Act classes brain-computer interfaces as high-risk AI systems and imposes strict transparency and safety requirements on how neurotechnology is built and deployed in Europe. Japan’s own framework, shaped by the 2014 Act on the Safety of Regenerative Medicine, gives it a starting point for neurotechnology governance that other jurisdictions will watch.

Mental privacy and cognitive liberty

Mental privacy. Privacy law covers communications, meaning what a person says, writes and transmits. It does not cover thought, which until recently could not be read. A device that can decode neural patterns tied to political preference, sexual desire, religious belief or emotional response reads information no law currently treats as protected. “Cognitive liberty”, the right to mental self-determination free from unauthorized monitoring or manipulation, is the term lawyers have started using for the gap.

Consent and non-verbal patients. Many of the people with most to gain, those with severe paralysis, late-stage ALS or locked-in syndrome, cannot give informed consent in the usual way. A clinical team has to decide whether to go ahead with an implant that might let the patient communicate, when the patient cannot yet say yes or no to it.

Enhancement and inequality. If BCIs come to augment healthy cognition, the gap between the enhanced and everyone else could exceed today’s gaps in education and wealth.

Security. A networked implant that delivers stimulation to alter mood, suppress impulse or induce a cognitive state can be attacked like any other networked medical device, pacemakers included.

Identity at the interface

Reading from the brain is one thing. Writing to it, which DBS already does for mood, and connecting two brains to each other, which has been tried in the lab, raise harder questions about where one person ends, and clinicians and courts will have to answer them case by case.

Neuralink has publicly discussed brain-to-brain communication as a long-term objective. Research teams have demonstrated rudimentary brain-to-brain interfaces in the lab, with one person’s neural signal triggering a motor response in another.

The summit has a session on this, titled “The No Body Problem”.

Market size

Grand View Research projects the global BCI market will reach $8-12 billion by 2030, driven by medical device approvals, consumer adoption, and enterprise uses in defense, aviation and other high-performance settings. Neuralink’s valuation has exceeded $8 billion. Synchron has raised over $270 million. Kernel, Paradromics and a crowd of startups compete across the range, from non-invasive headsets to high-channel-count implants.

Most of the near-term revenue is medical. Further out, the companies are talking about workforce augmentation, human-AI cognitive integration and communication that bypasses language, with AI models reading neural signals in real time and feeding information back to the user.

Join the conversation

On April 26, 2026, the Tech for Impact Summit convenes senior executives, policymakers and technologists at Tokyo Garden Terrace Kioi Conference. The summit’s theme is “Beyond Boundaries: Building 2050 Together”.

“The No Body Problem” session covers the BCI questions above: mental privacy, consent and what happens to identity at the interface.

Among the confirmed speakers: Taro Kono (former Minister of Digital Affairs), Charles Hoskinson (Cardano), Yoshito Hori (GLOBIS), Kathy Matsui (MPower Partners), Ken Suzuki (SmartNews), Jesper Koll (Monex Group), Sota Watanabe (Astar/Startale), and Hiroshi Aoi (Marui Group).

The discussion is aimed at leaders of healthcare enterprises, technology companies and organizations working on the governance of emerging neurotechnologies.

Explore partnership and membership opportunities →

Watch highlights from previous summits: youtu.be/ujy7ZXflrt4

---

The Tech for Impact Summit is an invitation-only executive gathering taking place April 26, 2026, in Tokyo as a partner event of SusHi Tech Tokyo. Learn more at tech4impactsummit.com.